Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease

Author:
Steven Sorscher Wake Forest School of Medicine, Winston-Salem, North Carolina Email: ssorsche@wakehealth.edu

Search for other papers by Steven Sorscher in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 19: Issue 6
Online Publication Date:
30 Jun 2021
DOI:
https://doi.org/10.6004/jnccn.2021.7053
Restricted access
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Wolff AC, Hammond EH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 2018;36:2105–2122.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Gradishar WJ, Anderson BO, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 6. 2020. Accessed September 8, 2020. To view the most recent version, visit NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38:3987–3998.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Press M, Slamon DJ. Controversies in HER2 oncogene testing: what constitutes a true positive result in patients with breast cancer? Letter to the editor: the authors respond. Accessed October 1, 2020. Available at: https://www.gotoper.com/publications/ajho/2017/2017october/controversies-in-her2-oncogene-testing-what-constitutes-a-true-positive-result-in-patients-with-breast-cancer

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380:617–628.

  • 6.

    Johnston SDR, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal woman with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol 2021;39:79–89.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Article Category:
Letter
Print Publication Date:
01 Jun 2021
Online Publication Date:
30 Jun 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1493 394 4
PDF Downloads 611 64 6
EPUB Downloads 0 0 0